Establishment Labs Holdings INC 8-K filings
NASDAQ
Establishment Labs has announced that the FDA has scheduled a pre-approval inspection of their manufacturing facility for Motiva Implants during the second quarter of 2024.
NASDAQ
Establishment Labs announced its fourth quarter and full year 2023 financial results, showing a revenue decrease but providing positive guidance for 2024.
NASDAQ
8-K: Establishment Labs Secures Amended Credit Agreement, Extends Loan Deadlines and Modifies Milestones
Establishment Labs has amended its credit agreement, extending loan deadlines and modifying financial milestones for accessing additional funding.
NASDAQ
Establishment Labs has filed a prospectus supplement for the offering of up to 2 million common shares by existing shareholders.